Connect with us

Technology

Couchbase Announces Fourth Quarter and Fiscal 2025 Financial Results

Published

on

SANTA CLARA, Calif., Feb. 25, 2025 /PRNewswire/ — Couchbase, Inc. (NASDAQ: BASE), the developer data platform for critical applications in our AI world, today announced financial results for its fourth quarter and fiscal year ended January 31, 2025.

“We finished fiscal 2025 on a strong note, including the highest quarterly free cash flow and net new ARR results in company history,” said Matt Cain, Chair, President and CEO of Couchbase. “We delivered top- and bottom-line outcomes that exceeded the high end of our outlook, saw robust expansions and migrations, and made further progress with Capella uptake. I’m pleased with the team’s execution in the quarter and confident in our ability to continue our momentum in fiscal 2026.”

Fourth Quarter Fiscal 2025 Financial Highlights

Revenue: Total revenue for the quarter was $54.9 million, an increase of 10% year-over-year. Subscription revenue for the quarter was $52.8 million, an increase of 10% year-over-year.Annual recurring revenue (ARR): Total ARR as of January 31, 2025 was $237.9 million, an increase of 17% year-over-year as reported and on a constant currency basis. Relative to currency rates underpinning the quarter and full year guidance, total ARR was $239.8 million. See the section titled “Key Business Metrics” below for details.Gross margin: Gross margin for the quarter was 88.6%, compared to 89.7% for the fourth quarter of fiscal 2024. Non-GAAP gross margin for the quarter was 89.4%, compared to 90.4% for the fourth quarter of fiscal 2024. See the section titled “Use of Non-GAAP Financial Measures” and the tables titled “Reconciliation of GAAP to Non-GAAP Results” below for details.Loss from operations: Loss from operations for the quarter was $15.8 million, compared to $22.6 million for the fourth quarter of fiscal 2024. Non-GAAP operating loss for the quarter was $0.1 million, compared to $4.1 million for the fourth quarter of fiscal 2024.Cash flow: Cash flow provided by operating activities for the quarter was $4.4 million, compared to cash flow used in operating activities of $6.5 million in the fourth quarter of fiscal 2024. Capital expenditures were $0.4 million during the quarter, leading to free cash flow of $4.0 million, compared to negative free cash flow of $7.7 million in the fourth quarter of fiscal 2024.Remaining performance obligations (RPO): RPO as of January 31, 2025 was $251.1 million, an increase of 4% year-over-year.

Full Year Fiscal 2025 Financial Highlights

Revenue: Total revenue for the year was $209.5 million, an increase of 16% year-over-year. Subscription revenue for the year was $200.4 million, an increase of 17% year-over-year.Gross margin: Gross margin for the year was 88.1%, compared to 87.7% for fiscal 2024. Non-GAAP gross margin for the year was 88.9%, compared to 88.5% for fiscal 2024.Loss from operations: Loss from operations for the year was $78.7 million, compared to $84.5 million for fiscal 2024. Non-GAAP operating loss for the year was $14.4 million, compared to $31.3 million for fiscal 2024.Cash flow: Cash flow used in operating activities for the year was $15.8 million, compared to cash flow used in operating activities of $26.9 million in fiscal 2024. Capital expenditures were $3.0 million during the year, leading to negative free cash flow of $18.8 million, compared to negative free cash flow of $31.6 million in fiscal 2024.

Recent Business Highlights

Launched the private preview of Capella AI Services to help customers build and deploy secure agentic applications while reducing development complexity and operational costs. The offering empowers developers to more easily build agents by giving them control over RAG workflows, access to AI models, and management of agent transcripts and metadata for data governance. With simplified workflows and integrated AI models, everything developers need is available in a single platform.Announced that Couchbase is helping enterprises accelerate the development of agentic AI applications with NVIDIA AI. Capella AI Model Services have integrated with NVIDIA NIM microservices, part of the NVIDIA AI Enterprise software platform, to offer a safe and fast way for organizations to build, deploy and evolve AI-powered applications. This integration gives customers the flexibility to run their preferred generative AI models while delivering optimized performance, security, support and reliability for AI workloads.Introduced the availability of Capella Analytics Services on Google Cloud, empowering enterprises to analyze operational JSON data at scale, driving faster, smarter decisions in an AI world. Built on Google’s C4A instances with Arm-based processors and Titanium SSDs, Capella Analytics Services addresses the historical challenges of incorporating JSON data into analytics, machine learning, and AI, better enabling developers to build cutting-edge AI-powered applications.Earned prestigious industry recognition, including placement among CRN’s 20 Coolest Cloud Software Companies of 2025 and multiple product awards for Capella, highlighted by SiliconANGLE Media’s Most Innovative Database, UK IT Industry’s Cloud Innovation of the Year award, and a DEVIES award for best innovation in data storage and management.

Financial Outlook

For the first quarter and full year of fiscal 2026, Couchbase expects:

Q1 FY2026 Outlook

FY2026 Outlook

Total Revenue

$55.1-55.9 million

$228.0-232.0 million

Total ARR

$242.9-245.9 million

$273.6-278.6 million

Non-GAAP Operating Loss

$5.4-4.4 million

$13.4-8.4 million

The guidance provided above is based on several assumptions that are subject to change and many of which are outside our control. If actual results vary from these assumptions, our expectations may change. There can be no assurance that we will achieve these results.

Couchbase is not able, at this time, to provide GAAP targets for operating loss for the first quarter or full year of fiscal 2026 because of the difficulty of estimating certain items excluded from non-GAAP operating loss that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

Conference Call Information

Couchbase will host a live webcast at 1:30 p.m. Pacific Time (or 4:30 p.m. Eastern Time) on Tuesday, February 25, 2025, to discuss its financial results and business highlights. The conference call can be accessed by dialing 877-407-8029 from the United States, or +1 201-689-8029 from international locations. The live webcast and a webcast replay can be accessed from the investor relations page of Couchbase’s website at investors.couchbase.com.

About Couchbase

As industries race to embrace AI, traditional database solutions fall short of rising demands for versatility, performance and affordability. Couchbase is seizing the opportunity to lead with Capella, the developer data platform architected for critical applications in our AI world. By uniting transactional, analytical, mobile and AI workloads into a seamless, fully-managed solution, Couchbase empowers developers and enterprises to build and scale applications and AI agents with complete flexibility – delivering exceptional performance, scalability and cost-efficiency from cloud to edge and everything in between. Couchbase enables organizations to unlock innovation, accelerate AI transformation and redefine customer experiences wherever they happen. Discover why Couchbase is the foundation of critical everyday applications by visiting www.couchbase.com and following us on LinkedIn and X.

Couchbase has used, and intends to continue using, its investor relations website and the corporate blog at blog.couchbase.com to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the corporate blog in addition to following our press releases, SEC filings and public conference calls and webcasts.

Use of Non-GAAP Financial Measures

In addition to our financial information presented in accordance with GAAP, we believe certain non-GAAP financial measures are useful to investors in evaluating our operating performance. We use certain non-GAAP financial measures, collectively, to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, may be helpful to investors because they provide consistency and comparability with past financial performance and meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. Non-GAAP financial measures are presented for supplemental informational purposes only, have limitations as analytical tools and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP, and may be different from similarly-titled non-GAAP financial measures used by other companies. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures (provided in the financial statement tables included in this press release), and not to rely on any single financial measure to evaluate our business.

Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating loss, non-GAAP operating margin, non-GAAP net income (loss) and non-GAAP net income (loss) per share: We define these non-GAAP financial measures as their respective GAAP measures, excluding expenses related to stock-based compensation expense, employer payroll taxes on employee stock transactions, restructuring charges and impairment of capitalized internal-use software. We use these non-GAAP financial measures in conjunction with GAAP measures to assess our performance, including in the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our financial performance.

For the fourth quarter of fiscal 2024, we excluded the impairment of capitalized internal-use software, a non-cash operating expense, from our non-GAAP results as it is not reflective of ongoing operating results. This impairment charge related to certain previously capitalized internal-use software that we determined would no longer be placed into service. Prior period non-GAAP financial measures have not been adjusted to reflect this change as we did not incur impairment of capitalized internal-use software in any prior period presented.

Free cash flow: We define free cash flow as cash provided by or used in operating activities less additions to property and equipment, which includes capitalized internal-use software costs. We believe free cash flow is a useful indicator of liquidity that provides our management, board of directors and investors with information about our future ability to generate or use cash to enhance the strength of our balance sheet and further invest in our business and pursue potential strategic initiatives. 

Please see the reconciliation tables at the end of this press release for the reconciliation of GAAP and non-GAAP results.

Key Business Metrics

We review a number of operating and financial metrics, including ARR, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions.

We define ARR as of a given date as the annualized recurring revenue that we would contractually receive from our customers in the month ending 12 months following such date. Based on historical experience with customers, we assume all contracts will be renewed at the same levels unless we receive notification of non-renewal and are no longer in negotiations prior to the measurement date. For Capella products, ARR in a customer’s initial year is calculated as the greater of: (i) initial year contract revenue as described above or (ii) annualized prior 90 days of actual consumption; and ARR for subsequent years is calculated with method (ii). ARR excludes services revenue.

Prior to fiscal 2025, ARR excluded on-demand revenue and, for Capella products in a customer’s initial year, ARR was calculated solely on the basis of initial year contract revenue. The reason for these changes is to better reflect ARR where usage rates or timing of purchases may be uneven and to better align with how ARR is used to measure the performance of the business. ARR for prior periods has not been adjusted to reflect this change as it is not material to any period previously presented.

ARR should be viewed independently of revenue, and does not represent our revenue under GAAP on an annualized basis, as it is an operating metric that can be impacted by contract start and end dates and renewal dates. ARR is not intended to be a replacement for forecasts of revenue. Although we seek to increase ARR as part of our strategy of targeting large enterprise customers, this metric may fluctuate from period to period based on our ability to acquire new customers, expand within our existing customers and consumption dynamics. We believe that ARR is an important indicator of the growth and performance of our business.

We also attempt to represent the changes in the underlying business operations by eliminating fluctuations caused by changes in foreign currency exchange rates within the current period. We calculate constant currency growth rates by applying the applicable prior period exchange rates to current period results.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include, but are not limited to, quotations of management, the section titled “Financial Outlook” above and statements about the expected client demand for and benefits of our offerings, the impact of our recently-released and planned products and services and our market position, strategies and potential market opportunities. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “continue,” “could,” “potential,” “remain,” “may,” “might,” “will,” “would” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words. Forward-looking statements involve known and unknown risks, uncertainties and other factors, including factors beyond our control, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to: our history of net losses and ability to achieve or maintain profitability in the future; our ability to continue to grow on pace with historical rates; our ability to manage our growth effectively; intense competition and our ability to compete effectively; cost-effectively acquiring new customers or obtaining renewals, upgrades or expansions from our existing customers; the market for our products and services being highly competitive and evolving, and our future success depending on the growth and expansion of this market; our ability to innovate in response to changing customer needs, new technologies or other market requirements, including new capabilities, programs and partnerships and their impact on our customers and our business; our limited operating history, which makes it difficult to predict our future results of operations; the significant fluctuation of our future results of operations and ability to meet the expectations of analysts or investors; our significant reliance on revenue from subscriptions, which may decline and, the recognition of a significant portion of revenue from subscriptions over the term of the relevant subscription period, which means downturns or upturns in sales are not immediately reflected in full in our results of operations; and the impact of geopolitical and macroeconomic factors. Further information on risks that could cause actual results to differ materially from forecasted results are included in our filings with the Securities and Exchange Commission that we may file from time to time, including those more fully described in our Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024. Additional information will be made available in our Annual Report on Form 10-K for the fiscal year ended January 31, 2025 that will be filed with the Securities and Exchange Commission, which should be read in conjunction with this press release and the financial results included herein. Any forward-looking statements contained in this press release are based on assumptions that we believe to be reasonable as of this date. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Couchbase, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Revenue:

License

$                  6,464

$                  7,196

$                22,908

$                21,514

Support and other

46,317

40,865

177,502

150,040

Total subscription revenue

52,781

48,061

200,410

171,554

Services

2,141

2,028

9,056

8,483

     Total revenue

54,922

50,089

209,466

180,037

Cost of revenue:

Subscription(1)

4,838

3,580

18,116

14,647

Services(1)

1,420

1,560

6,843

7,435

Total cost of revenue

6,258

5,140

24,959

22,082

     Gross profit

48,664

44,949

184,507

157,955

Operating expenses:

Research and development(1)

17,873

16,491

70,576

64,069

Sales and marketing(1)

33,818

34,055

141,937

130,558

General and administrative(1)

12,806

11,840

50,649

42,663

Impairment of capitalized internal-use software

5,156

5,156

Restructuring(1)

46

Total operating expenses

64,497

67,542

263,162

242,492

Loss from operations

(15,833)

(22,593)

(78,655)

(84,537)

Interest expense

(14)

(60)

(43)

Other income, net

802

1,766

5,864

5,752

Loss before income taxes

(15,045)

(20,827)

(72,851)

(78,828)

     Provision for income taxes

566

575

1,802

1,355

          Net loss

$              (15,611)

$              (21,402)

$              (74,653)

$              (80,183)

Net loss per share, basic and diluted

$                  (0.30)

$                  (0.44)

$                  (1.45)

$                  (1.70)

Weighted-average shares used in computing net loss per share, basic and diluted

52,766

48,513

51,310

47,175

(1) Includes stock-based compensation expense as follows:

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Cost of revenue – subscription

$                       315

$                       148

$                     1,200

$                       707

Cost of revenue – services

101

116

455

529

Research and development

4,430

3,422

17,134

12,920

Sales and marketing

5,283

4,310

21,910

15,771

General and administrative

5,097

4,630

20,598

15,846

Restructuring

1

Total stock-based compensation expense

$                   15,226

$                   12,626

$                   61,297

$                   45,774

 

Couchbase, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

As of January 31, 2025

As of January 31, 2024

Assets

Current assets

Cash and cash equivalents

$                             30,536

$                             41,351

Short-term investments

116,635

112,281

Accounts receivable, net

49,242

44,848

Deferred commissions

16,774

15,421

Prepaid expenses and other current assets

15,206

10,385

Total current assets

228,393

224,286

Property and equipment, net

7,214

5,327

Operating lease right-of-use assets

3,935

4,848

Deferred commissions, noncurrent

19,602

11,400

Other assets

1,454

1,891

Total assets

$                           260,598

$                           247,752

Liabilities and Stockholders’ Equity

Current liabilities

Accounts payable

$                               2,186

$                               4,865

Accrued compensation and benefits

21,091

18,116

Other accrued expenses

8,443

4,581

Operating lease liabilities

1,356

3,208

Deferred revenue

94,252

81,736

Total current liabilities

127,328

112,506

Operating lease liabilities, noncurrent

2,960

2,078

Deferred revenue, noncurrent

2,694

2,747

Total liabilities

132,982

117,331

Stockholders’ equity

Preferred stock

Common stock

Additional paid-in capital

692,812

621,024

Accumulated other comprehensive income

116

56

Accumulated deficit

(565,312)

(490,659)

Total stockholders’ equity

127,616

130,421

Total liabilities and stockholders’ equity

$                           260,598

$                           247,752

 

Couchbase, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Cash flows from operating activities

Net loss

$              (15,611)

$              (21,402)

$              (74,653)

$              (80,183)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

760

390

2,280

2,424

Stock-based compensation, net of amounts capitalized

15,226

12,626

61,297

45,774

Amortization of deferred commissions

4,788

4,886

17,443

18,628

Non-cash lease expense

910

762

3,303

3,075

Impairment of capitalized internal-use software

5,156

5,156

Foreign currency transaction losses

626

116

857

765

Other

(379)

(973)

(2,248)

(3,553)

Changes in operating assets and liabilities:

Accounts receivable

(20,953)

(14,496)

(4,746)

(5,382)

Deferred commissions

(13,382)

(10,937)

(26,998)

(24,829)

Prepaid expenses and other assets

(4,672)

(3,111)

(4,835)

(2,274)

Accounts payable

(2,952)

1,712

(3,101)

3,447

Accrued compensation and benefits

8,820

8,989

3,030

5,472

Other Accrued Expenses

4,016

1,481

3,541

(1,516)

Operating lease liabilities

(959)

(828)

(3,460)

(3,389)

Deferred revenue

28,120

9,179

12,462

9,492

Net cash provided by (used in) operating activities

4,358

(6,450)

(15,828)

(26,893)

Cash flows from investing activities

Purchases of short-term investments

(25,362)

(40,704)

(100,976)

(131,160)

Maturities of short-term investments

18,000

39,322

99,144

151,296

Additions to property and equipment

(375)

(1,285)

(3,020)

(4,710)

Net cash (used in) provided by investing activities

(7,737)

(2,667)

(4,852)

15,426

Cash flows from financing activities

Proceeds from exercise of stock options

1,172

3,580

6,423

10,933

Proceeds from issuance of common stock under ESPP

3,515

2,000

Net cash provided by financing activities

1,172

3,580

9,938

12,933

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(288)

(19)

(616)

(561)

Net (decrease) increase in cash, cash equivalents and restricted cash

(2,495)

(5,556)

(11,358)

905

Cash, cash equivalents, and restricted cash at beginning of period

33,031

47,450

41,894

40,989

Cash, cash equivalents, and restricted cash at end of period

$                30,536

$                41,894

$                30,536

$                41,894

Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown above:

Cash and cash equivalents

$                30,536

$                41,351

$                30,536

$                41,351

Restricted cash included in other assets

543

543

Total cash, cash equivalents and restricted cash

$                30,536

$                41,894

$                30,536

$                41,894

 

Couchbase, Inc.

Reconciliation of GAAP to Non-GAAP Results

(in thousands, except per share data)

(unaudited)

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Reconciliation of GAAP gross profit to non-GAAP gross profit:

Total revenue

$               54,922

$               50,089

$            209,466

$            180,037

Gross profit

$               48,664

$               44,949

$            184,507

$            157,955

Add: Stock-based compensation expense

416

264

1,655

1,236

Add: Employer taxes on employee stock transactions

13

61

133

147

Non-GAAP gross profit

$               49,093

$               45,274

$            186,295

$            159,338

Gross margin

88.6 %

89.7 %

88.1 %

87.7 %

Non-GAAP gross margin

89.4 %

90.4 %

88.9 %

88.5 %

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Reconciliation of GAAP operating expenses to non-GAAP operating expenses:

GAAP research and development

$                17,873

$                16,491

$                70,576

$                64,069

Less: Stock-based compensation expense

(4,430)

(3,422)

(17,134)

(12,920)

Less: Employer taxes on employee stock transactions

(122)

(181)

(707)

(611)

Non-GAAP research and development

$                13,321

$                12,888

$                52,735

$                50,538

GAAP sales and marketing

$                33,818

$                34,055

$              141,937

$              130,558

Less: Stock-based compensation expense

(5,283)

(4,310)

(21,910)

(15,771)

Less: Employer taxes on employee stock transactions

(269)

(377)

(1,647)

(1,154)

Non-GAAP sales and marketing

$                28,266

$                29,368

$              118,380

$              113,633

GAAP general and administrative

$                12,806

$                11,840

$                50,649

$                42,663

Less: Stock-based compensation expense

(5,097)

(4,630)

(20,598)

(15,846)

Less: Employer taxes on employee stock transactions

(59)

(77)

(450)

(341)

Non-GAAP general and administrative

$                  7,650

$                  7,133

$                29,601

$                26,476

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Reconciliation of GAAP loss from operations to non-GAAP loss from operations:

Total revenue

$               54,922

$               50,089

$             209,466

$            180,037

Loss from operations

$              (15,833)

$              (22,593)

$              (78,655)

$             (84,537)

Add: Stock-based compensation expense

15,226

12,626

61,297

45,773

Add: Employer taxes on employee stock transactions

463

696

2,937

2,253

Add: Impairment of capitalized internal-use software

5,156

5,156

Add: Restructuring(2)

46

Non-GAAP loss from operations

$                    (144)

$                (4,115)

$              (14,421)

$             (31,309)

Operating margin

(29) %

(45) %

(38) %

(47) %

Non-GAAP operating margin

— %

(8) %

(7) %

(17) %

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Reconciliation of GAAP net loss to non-GAAP net income (loss):

Net loss

$                (15,611)

$              (21,402)

$              (74,653)

$              (80,183)

Add: Stock-based compensation expense

15,226

12,626

61,297

45,773

Add: Employer taxes on employee stock transactions

463

696

2,937

2,253

Add: Impairment of capitalized internal-use software

5,156

5,156

Add: Restructuring(2)

46

Non-GAAP net income (loss)

$                        78

$                (2,924)

$              (10,419)

$              (26,955)

GAAP net loss per share, basic and dilutive

$                    (0.30)

$                  (0.44)

$                  (1.45)

$                  (1.70)

Non-GAAP net income (loss) per share, basic and dilutive

$                        —

$                  (0.06)

$                  (0.20)

$                  (0.57)

Weighted average shares outstanding, basic

52,766

48,513

51,310

47,175

Weighted average shares outstanding, dilutive(3)

56,093

48,513

51,310

47,175

(2)

For the twelve months ended January 31, 2024, an immaterial amount of stock-based compensation expense related to restructuring charges was included in the restructuring expense line.

(3)

For periods where the Company is in a net loss position, basic and dilutive weighted average shares are equivalent.

The following table presents a reconciliation of free cash flow to net cash provided by (used in) operating activities, the most directly comparable GAAP measure (in thousands, unaudited):

Three Months Ended January 31,

Year Ended January 31,

2025

2024

2025

2024

Net cash provided by (used in) operating activities

$                  4,358

$                (6,450)

$              (15,828)

$               (26,893)

Less: Additions to property and equipment

(375)

(1,285)

(3,020)

(4,710)

Free cash flow

$                  3,983

$                (7,735)

$              (18,848)

$               (31,603)

Net cash (used in) provided by investing activities

$                (7,737)

$                (2,667)

$                (4,852)

$                15,426

Net cash provided by financing activities

$                  1,172

$                 3,580

$                 9,938

$                12,933

 

Couchbase, Inc.

Key Business Metrics

(in millions)

(unaudited)

As of:

April 30,

July 31,

Oct. 31,

Jan. 31,

April 30,

July 31,

Oct. 31,

Jan 31,

2023

2023

2023

2024

2024

2024

2024

2025

ARR

$     172.2

$     180.7

$     188.7

$     204.2

$     207.7

$     214.0

$     220.3

$     237.9

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/couchbase-announces-fourth-quarter-and-fiscal-2025-financial-results-302385147.html

SOURCE Couchbase, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple

Published

on

By

The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.

AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.

The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.

The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.

The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.

According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.

The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.

Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.

The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.

The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.

What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.

About HelloNation

HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html

SOURCE HelloNation

Continue Reading

Technology

CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group

Published

on

By

Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.

ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.

Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.

“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”

Key Challenges IT Leaders Face in Regulatory Response

Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:

Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.

Info-Tech’s Framework for Building a Regulatory IT Response Engine

To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:

Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.

Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.

The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.

For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html

SOURCE Info-Tech Research Group

Continue Reading

Technology

Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026

Published

on

By

LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.

The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.

https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw

About Atomera

Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap.  More information can be found at www.atomera.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html

SOURCE Atomera Incorporated

Continue Reading

Trending